Cranbrook Wealth Management »

Halozyme Therapeutics shares owned by Cranbrook Wealth Management

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Cranbrook Wealth Management from 13F filings

Historical chart of Cranbrook Wealth Management investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Cranbrook Wealth Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Cranbrook Wealth Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $745 13 57.31

More positions owned by Cranbrook Wealth Management

Vanguard Bd Index Fds Intermed Term (BIV)
Ishares Tr Core S&p500 Etf (IVV)
Ishares Tr Core Msci Eafe (IEFA)
Vanguard Index Fds Mid Cap Etf (VO)
Vanguard Charlotte Fds Total Int Bd Etf (BNDX)
Ishares Tr Core S&p Scp Etf (IJR)
Schwab Strategic Tr Intl Eqty Etf (SCHF)
Vanguard Index Fds Growth Etf (VUG)
Vanguard Index Fds Large Cap Etf (VV)
Vanguard Index Fds Value Etf (VTV)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Ishares Tr Eafe Grwth Etf (EFG)
Ishares Tr Core 1 5 Yr Usd (ISTB)
Vanguard Index Fds Mcap Vl Idxvip (VOE)
Ishares Gold Tr Ishares New (IAU)

View all positions for Cranbrook Wealth Management

Top funds holding Halozyme Therapeutics

BlackRock
BlackRock
Vanguard Group
State Street Corporation
Snyder Capital Management
Alliancebernstein
Artisan Partners Limited Partnership
Macquarie Group
Geode Capital Management
Jpmorgan Chase & Co
Congress Asset Management
Bank of America Corporation
Arrowpoint Asset Management
Handelsbanken Fonder AB
Invesco

View all funds holding Halozyme Therapeutics